← Eichor
Condition: Nab Paclitaxel Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Nab Paclitaxel

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT04138719QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Phase 2 · 1 location(s) · Fudan University · NCT06786026Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metas
Phase 2 · 30 location(s) · National Cancer Institute (NCI) · NCT03606967Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Ca
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07638436ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 1 location(s) · ProDa BioTech, LLC · NCT06182072Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Subop
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07340398QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07601178Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
Phase 2 · 1 location(s) · Susan E. Bates · NCT05241249Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Ri
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07436741A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and
Phase 2/Phase 3 · 2 location(s) · Hutchmed · NCT06361888Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Phase 2 · 1 location(s) · Japan Breast Cancer Research Group · NCT06793553Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With
Phase 2 · 9 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT04570943BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 · 17 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06917079Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone M
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06538896Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metas
Phase 2 · 1 location(s) · Fudan University · NCT06591650Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
Phase 2 · 1 location(s) · Xiaohua Wu · NCT06209294Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr
Phase 2 · 1 location(s) · Dai, Guanghai · NCT07392346Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT03964753ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06904378Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
Phase 2 · 1 location(s) · Loma Linda University · NCT03492671Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 3 · 31 location(s) · Immuneering Corporation · NCT07562152A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastati
Phase 1/Phase 2 · 1 location(s) · Theriva Biologics SL · NCT07701486Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Phase 2 · 1 location(s) · Sichuan University · NCT06403878AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative
Phase 3 · 1 location(s) · Akeso · NCT06767527BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P
Phase 2 · 3 location(s) · Mayo Clinic · NCT07226856Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Phase 2 · 1 location(s) · Columbia University · NCT07433673Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT07233252Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05981014A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advance
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07438106Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Phase 2 · 3 location(s) · Gulam Manji · NCT04543071
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.